Genomics BioSci & Tech. Co.Ltd.
Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; reproductive health and cancer testing services; and contract development and manufacturing services. Genomics BioSci & Tech. Co.,Ltd. was founded in 2001 and is based in New Taipei City, Taiwan.
Market Cap & Net Worth: Genomics BioSci & Tech. Co.Ltd. (4195)
Genomics BioSci & Tech. Co.Ltd. (TWO:4195) has a market capitalization of $53.10 Million (NT$1.76 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #22479 globally and #1288 in its home market, demonstrating a 1.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genomics BioSci & Tech. Co.Ltd.'s stock price NT$24.25 by its total outstanding shares 72448056 (72.45 Million).
Genomics BioSci & Tech. Co.Ltd. Market Cap History: 2015 to 2026
Genomics BioSci & Tech. Co.Ltd.'s market capitalization history from 2015 to 2026. Data shows growth from $56.25 Million to $53.10 Million (3.81% CAGR).
Genomics BioSci & Tech. Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genomics BioSci & Tech. Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
Genomics BioSci & Tech. Co.Ltd.'s market cap is 0.11 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $23.85 Million | $427.65 Million | $18.17 Million | 0.06x | 1.31x |
| 2020 | $40.32 Million | $443.18 Million | $619.00K | 0.09x | 65.13x |
| 2021 | $40.01 Million | $389.96 Million | $18.74 Million | 0.10x | 2.14x |
| 2022 | $42.05 Million | $419.00 Million | $71.60 Million | 0.10x | 0.59x |
| 2023 | $45.44 Million | $396.14 Million | -$168.07 Million | 0.11x | N/A |
Competitor Companies of 4195 by Market Capitalization
Companies near Genomics BioSci & Tech. Co.Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Genomics BioSci & Tech. Co.Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Genomics BioSci & Tech. Co.Ltd. Historical Marketcap From 2015 to 2026
Between 2015 and today, Genomics BioSci & Tech. Co.Ltd.'s market cap moved from $56.25 Million to $ 53.10 Million, with a yearly change of 3.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$53.10 Million | -5.64% |
| 2025 | NT$56.27 Million | +34.20% |
| 2024 | NT$41.93 Million | -7.71% |
| 2023 | NT$45.44 Million | +8.06% |
| 2022 | NT$42.05 Million | +5.10% |
| 2021 | NT$40.01 Million | -0.77% |
| 2020 | NT$40.32 Million | +69.07% |
| 2019 | NT$23.85 Million | +4.13% |
| 2018 | NT$22.90 Million | -51.85% |
| 2017 | NT$47.56 Million | +73.18% |
| 2016 | NT$27.47 Million | -51.17% |
| 2015 | NT$56.25 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Genomics BioSci & Tech. Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.10 Million USD |
| MoneyControl | $53.10 Million USD |
| MarketWatch | $53.10 Million USD |
| marketcap.company | $53.10 Million USD |
| Reuters | $53.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.